Accuray Announces New Treatment Planning Service Offering
"Accuray's treatment planning service will help our customers controlcosts and increase their patient throughput, while also helping Accuray toenhance its recurring revenue," said Euan S. Thomson, Ph.D., president and CEOof Accuray Incorporated. "Our data indicate that our users will treat morethan 20,000 patients during the 2008 calendar year. At current reimbursementlevels, that translates into a potential market opportunity of more than$50 million. As more CyberKnife Systems are installed and treatment numbersincrease, the market will continue to expand."
Georgetown's CyberKnife Center, one of the top five busiest CyberKnifeCenters in the world, has already signed on for Accuray's new treatmentplanning service. Treatment planning services are approved for reimbursementthrough Medicare and other private carriers.
"We're looking forward to utilizing Accuray's treatment planning serviceto enhance our operational effectiveness and address the global shortage ofmedical physicists paired with the growing demand for CyberKniferadiosurgery," said Linda F. Winger, vice president of professional servicesand research administration at Georgetown University Hospital. "The treatmentplanning service will allow our physicists to focus on our long term growthand quality of care by transferring the time-consuming daily task of treatmentplanning to an external team of experts."
Accuray's treatment planning service will also enable new customers tobegin delivering CyberKnife treatments earlier by allowing their in-housestaff to focus on the important role of site commissioning and qualityassurance while transferring the planning component to Accuray's treatmentplanning group's Board Certified medical physicists.
About the CyberKnife(R) Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world's only roboticradiosurgery system designed to treat tumors anywhere in the bodynon-invasively. Using continual image guidance technology and computercontrolled robotic mobility, the CyberKnife System automatically tracks,detects and corrects for tumor and patient movement in real-time throughoutthe treatment. This enables the CyberKnife System to deliver high-doseradiation with pinpoint precision, which minimizes damage to surroundinghealthy tissue and eliminates the need for invasive head or body stabilizationframes.
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is aglobal leader in the field of radiosurgery dedicated to providing an improvedquality of life and a non-surgical treatment option for those diagnosed withcancer. Accuray develops and markets the CyberKnife Robotic RadiosurgerySystem, which extends the benefits of radiosurgery to include extracranialtumors, including those in the spine, lung, prostate, liver and pancreas. Todate, the CyberKnife System has been used to treat more than 40,000 patientsworldwide and currently more than 100 systems have been installed in leadinghospitals in the Americas, Europe and Asia. For more information, please visithttp://www.accuray.com.
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involverisks and uncertainties, including uncertainties associated with the medicaldevice industry. Except for the historical information contained herein, thematters set forth in this press release, c
You May Also Like